These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 9619838)
1. Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts. Kilbey A; Bartholomew C Oncogene; 1998 Apr; 16(17):2287-91. PubMed ID: 9619838 [TBL] [Abstract][Full Text] [Related]
2. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Bartholomew C; Kilbey A; Clark AM; Walker M Oncogene; 1997 Feb; 14(5):569-77. PubMed ID: 9053855 [TBL] [Abstract][Full Text] [Related]
3. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Kurokawa M; Ogawa S; Tanaka T; Mitani K; Yazaki Y; Witte ON; Hirai H Oncogene; 1995 Sep; 11(5):833-40. PubMed ID: 7675444 [TBL] [Abstract][Full Text] [Related]
4. Solution structure of a Zap1 zinc-responsive domain provides insights into metalloregulatory transcriptional repression in Saccharomyces cerevisiae. Wang Z; Feng LS; Matskevich V; Venkataraman K; Parasuram P; Laity JH J Mol Biol; 2006 Apr; 357(4):1167-83. PubMed ID: 16483601 [TBL] [Abstract][Full Text] [Related]
5. UXT interacts with the transcriptional repressor protein EVI1 and suppresses cell transformation. McGilvray R; Walker M; Bartholomew C FEBS J; 2007 Aug; 274(15):3960-71. PubMed ID: 17635584 [TBL] [Abstract][Full Text] [Related]
6. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain. Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154 [TBL] [Abstract][Full Text] [Related]
7. The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG. Funabiki T; Kreider BL; Ihle JN Oncogene; 1994 Jun; 9(6):1575-81. PubMed ID: 8183551 [TBL] [Abstract][Full Text] [Related]
8. Transcriptional repression by the proto-oncogene BCL-6. Seyfert VL; Allman D; He Y; Staudt LM Oncogene; 1996 Jun; 12(11):2331-42. PubMed ID: 8649773 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Mitani K Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182 [TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of human ZNF274 cDNA, which encodes a novel kruppel-type zinc-finger protein having nucleolar targeting ability. Yano K; Ueki N; Oda T; Seki N; Masuho Y; Muramatsu M Genomics; 2000 Apr; 65(1):75-80. PubMed ID: 10777669 [TBL] [Abstract][Full Text] [Related]
16. The Evi-1 zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes. Morishita K; Parganas E; Parham DM; Matsugi T; Ihle JN Oncogene; 1990 Sep; 5(9):1419-23. PubMed ID: 1699199 [TBL] [Abstract][Full Text] [Related]
17. EVI-1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN1-28 CTCATCTTC. Morishita K; Suzukawa K; Taki T; Ihle JN; Yokota J Oncogene; 1995 May; 10(10):1961-7. PubMed ID: 7761097 [TBL] [Abstract][Full Text] [Related]
18. Functional domains of the TGF-beta-inducible transcription factor Tieg3 and detection of two putative nuclear localization signals within the zinc finger DNA-binding domain. Spittau B; Wang Z; Boinska D; Krieglstein K J Cell Biochem; 2007 Jun; 101(3):712-22. PubMed ID: 17252542 [TBL] [Abstract][Full Text] [Related]
19. A domain necessary for the transforming activity of SnoN is required for specific DNA binding, transcriptional repression and interaction with TAF(II)110. Cohen SB; Nicol R; Stavnezer E Oncogene; 1998 Nov; 17(19):2505-13. PubMed ID: 9824161 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Kurokawa M; Tanaka T; Tanaka K; Ogawa S; Mitani K; Yazaki Y; Hirai H Oncogene; 1996 Feb; 12(4):883-92. PubMed ID: 8632911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]